Start with the ingredient
Hirudin is a peptide substance first identified from leeches. In pharmacological research it is a direct thrombin inhibitor. “Natural” describes an origin concept; it does not guarantee safety for everyone or the effects of a particular oral product.
Clinical use of live leeches, research on the hirudin ingredient, and oral finished products such as Hirumax or Zhitongwang are separate topics. The ingredient guide covers sources, mechanisms, raw-material differences and safety in more detail.
The medical and medicinal history of leeches
From traditional practice to modern medicine, the use of leeches has changed as medicine developed. Explore that history through three periods.
19th centuryLeeches were widely used in bloodletting
Bloodletting is historical context, not guidance for modern self-treatment.
20th centuryTraditional use gradually declined
Research methods and medical uses changed as medicine moved beyond traditional practice.
Modern practiceRenewed attention in specific clinical settings
Leech use in specific clinical settings is not the same as an oral hirudin product.
Person and brand context: Zhou Weihai
The brand material describes Zhou Weihai as the “father of natural hirudin” and the “father of natural hirudin in China.” These are descriptions used in the supplied material, not academic titles awarded or independently verified by this website.
The portrait helps explain the source’s narrative, but it is not evidence of medical-institution endorsement, Hong Kong product approval or clinical effects of a finished product. Check the current physical label and complete specification for product information.
How should the five source descriptions be read?
The original graphic presents five descriptions under a heading about natural-hirudin effects. Explore these themes with reading notes. Ingredient research and brand descriptions are not established effects of the two oral finished products.
01 / “Purifying the blood environment”
Brand-material description — not verified product effects
The material describes regulating blood lipids and cholesterol, clearing excess metabolic waste from the blood, and keeping blood clear.
Reading note and evidence limits
“Clean blood” and “clearing waste” are not quantified clinical outcomes for this product. Blood lipids and cholesterol require testing and professional assessment; the supplied graphic does not establish a lipid-lowering effect for an oral product.
02 / “Promoting blood circulation”
Brand-material description — not verified product effects
The material describes increasing blood oxygen, speeding blood flow, easing cardiovascular workload, and balancing pressure on vessel walls.
Reading note and evidence limits
An ingredient’s anticoagulant mechanism does not by itself establish increased blood oxygen, improved circulation or reduced cardiovascular workload. Evidence must address the actual finished product, its use and the specific outcome.
03 / “Caring for vessel walls”
Brand-material description — not verified product effects
The material describes removing excess free radicals, maintaining vessel health, and reducing the chance of damage to the inner vessel wall.
Reading note and evidence limits
Free-radical activity and protection of blood vessels are separate evidence questions. General antioxidant research cannot be treated as proof of effects for Hirumax or Zhitongwang.
04 / “Maintaining vessel elasticity”
Brand-material description — not verified product effects
The material describes maintaining flexible blood vessels, supporting vessel function, and improving vessel stiffness.
Reading note and evidence limits
Vessel elasticity and stiffness require clinical measurement. The source does not provide clinical evidence that these two finished products improve vessel stiffness; this site makes no such guarantee.
05 / “Keeping small blood vessels flowing”
Brand-material description — not verified product effects
The material describes maintaining blood flow, improving microcirculation, reducing blood stasis, and supporting cardiovascular and cerebrovascular health.
Reading note and evidence limits
Anticoagulation and directly dissolving an existing clot are different processes. This description does not establish that an oral product can unblock vessels, treat clots or prevent cardiovascular or cerebrovascular disease.
Nine health concerns — not a product-suitability list.
A supplied graphic asks which groups might be helped and lists nine situations. The labels below come from that material. They are not verified indications or a statement that everyone with those symptoms or habits should use a hirudin product.
Source wording, not a substitute for laboratory results or a medical diagnosis.
Existing disease and medicines need clinical assessment; a product should not replace treatment.
Causes vary. Persistent or sudden symptoms need professional assessment.
Review each measured value and follow a clinical management plan; this is not evidence of product suitability.
A health product does not cancel the risks of smoking or alcohol.
Skin symptoms are not a basis for choosing a product associated with anticoagulant research.
The diagnosis and risks must be identified; a graphic is not a basis for self-selection.
Product promises should not replace attention to sleep, activity and diet.
Weight management needs an overall assessment; this site makes no weight-loss or treatment claim.
Blood pressure, glucose and lipids: understand each measure.
The material groups high blood pressure, high blood glucose and high blood lipids as “three highs,” noting that they may occur separately or together. Measurements, medical history and personal risks need separate assessment rather than a broad label replacing diagnosis.
High blood pressure
Source description
The material describes high blood pressure as often accompanying lipid and glycation-related metabolic disturbances and changes involving the heart, brain, kidneys and retina.
This is a general source description, not a statement that every patient has the same complications or that a product can manage them.
High blood glucose
Source description
The material describes long-term high blood glucose as affecting tissues and organs and leading to acute or chronic complications.
Individual risk depends on test results, medical history and professional assessment. This does not establish glucose control by a hirudin product.
High blood lipids
Source description
The material mentions atherosclerosis, coronary heart disease and acute pancreatitis in relation to high blood lipids.
Different lipid measurements and risks should not be conflated. A clinician should interpret them; the graphic does not establish lipid improvement by the finished product.
Safety and evidence limits
Natural origin, personal titles, historical stories, process patents and product effects are different matters. Pharmacological research may use formulations, doses or routes different from an oral finished product, so it cannot be directly converted into purchase or use advice.
If you take medicines, have bleeding or kidney concerns, are preparing for surgery, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not stop prescribed medicines or replace diagnosis and treatment with a health product. Acute chest pain, difficulty breathing or sudden neurological symptoms require urgent medical attention.